ID 56 - Kwas pantotenowy

PL: Kwas pantotenowy
EN: Panthothenic acid
Pdf: pantothenic acid

Oświadczenie (4)

Oświadczenie (2)

1. Charakterystyka żywności / składnika

The food constituent that is the subject of the health claim is pantothenic acid (vitamin B5) which is a well recognised nutrient and is measurable in foods by established methods.
Pantothenic acid occurs naturally in foods and is authorised for addition to foods (Annex I of Regulation (EC) No 1925/20063 and Annex I of Directive 2002/46/EC4). This evaluation applies to pantothenic acid naturally present in foods and to those forms authorised for addition to foods (Annex II of Regulation (EC) No 1925/2006 and Annex II of Directive 2002/46/EC).
The Panel considers that the food constituent, pantothenic acid, which is the subject of the health claim, is sufficiently characterised.

2.1. Metabolizm energetyczny (ID 56, 59, 60, 64, 171, 172, 208)

The claimed effects are “fat and carbohydrate metabolism”, “macronutrient metabolism”, “energy metabolism”, “metabolism of fat” and “carbohydrate and amino-acid metabolism”. The Panel assumes that the target population is the general population.
The Panel notes that, in the context of the proposed wordings, “energy metabolism” and “macronutrient metabolism” relate to energy-yielding metabolism of macronutrients.
The Panel considers that normal energy-yielding metabolism is beneficial to human health.

3. Naukowe uzasadnienia wpływu na zdrowie człowieka

Pantothenic acid is required for the synthesis of coenzyme A (CoA), a cofactor and acyl group carrier for many enzymatic processes and for the synthesis of the prosthetic group of the acyl carrier protein (ACP), a component of the fatty acid synthesis complex. Most tissues transport pantothenic acid into cells for the synthesis of CoA (IoM, 1998). The evidence for essentiality of pantothenic acid consists of its well known role in cellular biochemistry.
Deficiency symptoms have only been observed in experimental settings such as giving a pantothenic acid metabolic antagonist and not in dietary studies. Deficiency symptoms included irritability, restlessness, fatigue, apathy, malaise, sleep disturbances, numbness and muscle cramps (IoM, 1998).

3.1. Metabolizm energetyczny (ID 56, 59, 60, 64, 171, 172, 208)

Pantothenic acid as a component of CoA and ACP has central roles in energy, carbohydrate, protein and lipid metabolism (IoM, 1998; SCF, 2002; EVM, 2002; Sadler at al., 1999).
The Panel concludes that a cause and effect relationship has been established between the dietary intake of pantothenic acid and normal energy-yielding metabolism. However, the evidence provided does not establish that inadequate intake of pantothenic acid leading to impaired energy-yielding metabolism occurs in the general EU population.

4.1. Metabolizm energetyczny (ID 56, 59, 60, 64, 171, 172, 208)

The Panel considers that the following wording reflects the scientific evidence: “Pantothenic acid contributes to normal energy-yielding metabolism”.

5. Warunki i możliwe ograniczenia stosowania oświadczenia

The Panel considers that in order to bear the claim a food should be at least a source of pantothenic acid as per Annex to Regulation (EC) No 1924/2006. Such amounts can be easily consumed as part of
a balanced diet. Tolerable Upper Intake Levels have not been established for pantothenic acid in children, adolescents and adults.

Warunki i możliwe ograniczenia stosowania oświadczenia

Must at least be a source of vitamin/s as per annex to regulation 1924/2006